Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kellie Grove

Nurse Practitioner, Family Tupelo, MS Nurse Practitioner

NPI 1811472681 CMS profile 11028439

860 South Madison Street, Tupelo, MS 38801

Open in the dashboard

General payments

$8,511

466 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kellie Grove of Tupelo, MS is reported in the CMS Open Payments database as having received $8,511 across 466 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,226 164
2024 General $2,568 140
2023 General $1,615 83
2022 General $624 48
2021 General $478 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kellie Grove
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kellie Grove were reported at $3,226. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kellie Grove Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $478 $124 $35–$379 $132
2022 $624 $141 $44–$430 $149
2023 $1,615 $154 $49–$476 $160
2024 $2,568 $165 $51–$504 $164
2025 $3,226 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,564 65 payments
  2. GlaxoSmithKline, LLC. $1,508 134 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $856 49 payments
  4. Harmony Biosciences LLC $469 17 payments
  5. Merck Sharp & Dohme Corporation $468 25 payments
  6. Genzyme Corporation $403 19 payments
  7. Jazz Pharmaceuticals Inc. $392 18 payments
  8. Regeneron Healthcare Solutions, Inc. $383 18 payments
  9. Mallinckrodt Hospital Products Inc. $315 17 payments
  10. Inspire Medical Systems, Inc. $301 5 payments
  11. Other $1,853 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,500 465 payments
  2. Education $11 1 payment
Products named General payments · program years 2021–2025
  1. FASENRA $1,205 43 payments
  2. TRELEGY ELLIPTA $1,032 103 payments
  3. BREZTRI $616 9 payments
  4. AIRSUPRA $574 6 payments
  5. TEZSPIRE $557 14 payments
  6. NUCALA $449 28 payments
  7. DUPIXENT $403 19 payments
  8. XYWAV $370 17 payments
  9. ZERBAXA $318 19 payments
  10. ACTHAR $315 17 payments
  11. Other $5,072 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,046

Median for Nurse Practitioner: 389

Drug cost

$295,270

Median for Nurse Practitioner: $21,885

Branded share of claims

70.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 89 $65,431
Xolair Omalizumab Brand 22 $46,892
Tadalafil Generic 18 $34,631
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 37 $21,243
Breo Ellipta Fluticasone/Vilanterol Brand 35 $17,416
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 27 $16,911
Incruse Ellipta Umeclidinium Bromide Brand 47 $16,110
Spiriva Handihaler Tiotropium Bromide Brand 16 $10,750
Spiriva Respimat Tiotropium Bromide Brand 16 $10,703
Eliquis Apixaban Brand 17 $10,268

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$33,595

Medicare's payments for the services billed

Medicare patients

588

Average age 72

Services billed

862

322 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 48%
Diabetes 42%
COPD 41%
Chronic kidney disease 30%
Depression 27%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
$334 — —
DUPIXENT
$236 — —
OFEV
$210 — —
WAKIX
$181 — —
ACTHAR
$177 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

466 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record